News | January 22, 2025
Sunshine Biopharma launches Olanzapine and Olanzapine ODT
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Investment will fund expansion to meet rising demand for CRDMO services
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Increases speed to market for drug developers working on nucleic acid therapeutics
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Subscribe To Our Newsletter & Stay Updated
